Molecular staging of colorectal cancer

K-ras mutation analysis of lymph nodes upstages Dukes B patients

Jennifer S. Thebo, Anthony J. Senagore, David S. Reinhold, Susan R. Stapleton

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

PURPOSE. Multiple attempts have been made to improve the clinical/pathologic staging system of Dukes to focus adjuvant therapy decisions. The purpose of this study was to determine whether K-ras mutational status of regional nodes in patients with Dukes B2 colorectal cancer could be used to stage their disease more accurately. METHODS: Using formalin-fixed, paraffin-embedded archival material, tumor samples were screened for K-ras mutations using a mutation-specific polymerase chain reaction method, followed by gel electrophoresis in a 96-well array. Patients with Dukes B2 tumors that have mutations in codon 12 or 13 of the K-ras gene were identified. RESULTS: Mutational analysis of the lymph nodes from these patients revealed an 80 percent (16/20) incidence of the same mutations in regional lymph nodes. None of the four patients with mutation-free nodes developed recurrence compared with 37.5 percent (6/16) with K-ras positive lymph nodes. CONCLUSIONS: The data suggest that patients with Dukes B2 colorectal cancers that have mutations in codon 12 or 13 of the K-ras gene are at high risk for the development of nodal metastases. Mutational analysis of the lymph nodes identifies high-risk patients who should be considered for adjuvant chemotherapy. Therefore, K-ras mutational analysis should be considered for molecular staging of colorectal cancer.

Original languageEnglish (US)
Pages (from-to)155-162
Number of pages8
JournalDiseases of the Colon and Rectum
Volume43
Issue number2
StatePublished - Feb 2000
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Lymph Nodes
Mutation
ras Genes
Codon
Adjuvant Chemotherapy
Paraffin
Formaldehyde
Electrophoresis
Neoplasms
Gels
Neoplasm Metastasis
Recurrence
Polymerase Chain Reaction
Incidence
Therapeutics

Keywords

  • AS-PCR
  • Colorectal cancer
  • K-ras
  • Lymph nodes
  • Micrometastasis
  • Staging

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Thebo, J. S., Senagore, A. J., Reinhold, D. S., & Stapleton, S. R. (2000). Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients. Diseases of the Colon and Rectum, 43(2), 155-162.

Molecular staging of colorectal cancer : K-ras mutation analysis of lymph nodes upstages Dukes B patients. / Thebo, Jennifer S.; Senagore, Anthony J.; Reinhold, David S.; Stapleton, Susan R.

In: Diseases of the Colon and Rectum, Vol. 43, No. 2, 02.2000, p. 155-162.

Research output: Contribution to journalArticle

Thebo, JS, Senagore, AJ, Reinhold, DS & Stapleton, SR 2000, 'Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients', Diseases of the Colon and Rectum, vol. 43, no. 2, pp. 155-162.
Thebo, Jennifer S. ; Senagore, Anthony J. ; Reinhold, David S. ; Stapleton, Susan R. / Molecular staging of colorectal cancer : K-ras mutation analysis of lymph nodes upstages Dukes B patients. In: Diseases of the Colon and Rectum. 2000 ; Vol. 43, No. 2. pp. 155-162.
@article{8f3ce73819024207b828c3eaa1f509bc,
title = "Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients",
abstract = "PURPOSE. Multiple attempts have been made to improve the clinical/pathologic staging system of Dukes to focus adjuvant therapy decisions. The purpose of this study was to determine whether K-ras mutational status of regional nodes in patients with Dukes B2 colorectal cancer could be used to stage their disease more accurately. METHODS: Using formalin-fixed, paraffin-embedded archival material, tumor samples were screened for K-ras mutations using a mutation-specific polymerase chain reaction method, followed by gel electrophoresis in a 96-well array. Patients with Dukes B2 tumors that have mutations in codon 12 or 13 of the K-ras gene were identified. RESULTS: Mutational analysis of the lymph nodes from these patients revealed an 80 percent (16/20) incidence of the same mutations in regional lymph nodes. None of the four patients with mutation-free nodes developed recurrence compared with 37.5 percent (6/16) with K-ras positive lymph nodes. CONCLUSIONS: The data suggest that patients with Dukes B2 colorectal cancers that have mutations in codon 12 or 13 of the K-ras gene are at high risk for the development of nodal metastases. Mutational analysis of the lymph nodes identifies high-risk patients who should be considered for adjuvant chemotherapy. Therefore, K-ras mutational analysis should be considered for molecular staging of colorectal cancer.",
keywords = "AS-PCR, Colorectal cancer, K-ras, Lymph nodes, Micrometastasis, Staging",
author = "Thebo, {Jennifer S.} and Senagore, {Anthony J.} and Reinhold, {David S.} and Stapleton, {Susan R.}",
year = "2000",
month = "2",
language = "English (US)",
volume = "43",
pages = "155--162",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Molecular staging of colorectal cancer

T2 - K-ras mutation analysis of lymph nodes upstages Dukes B patients

AU - Thebo, Jennifer S.

AU - Senagore, Anthony J.

AU - Reinhold, David S.

AU - Stapleton, Susan R.

PY - 2000/2

Y1 - 2000/2

N2 - PURPOSE. Multiple attempts have been made to improve the clinical/pathologic staging system of Dukes to focus adjuvant therapy decisions. The purpose of this study was to determine whether K-ras mutational status of regional nodes in patients with Dukes B2 colorectal cancer could be used to stage their disease more accurately. METHODS: Using formalin-fixed, paraffin-embedded archival material, tumor samples were screened for K-ras mutations using a mutation-specific polymerase chain reaction method, followed by gel electrophoresis in a 96-well array. Patients with Dukes B2 tumors that have mutations in codon 12 or 13 of the K-ras gene were identified. RESULTS: Mutational analysis of the lymph nodes from these patients revealed an 80 percent (16/20) incidence of the same mutations in regional lymph nodes. None of the four patients with mutation-free nodes developed recurrence compared with 37.5 percent (6/16) with K-ras positive lymph nodes. CONCLUSIONS: The data suggest that patients with Dukes B2 colorectal cancers that have mutations in codon 12 or 13 of the K-ras gene are at high risk for the development of nodal metastases. Mutational analysis of the lymph nodes identifies high-risk patients who should be considered for adjuvant chemotherapy. Therefore, K-ras mutational analysis should be considered for molecular staging of colorectal cancer.

AB - PURPOSE. Multiple attempts have been made to improve the clinical/pathologic staging system of Dukes to focus adjuvant therapy decisions. The purpose of this study was to determine whether K-ras mutational status of regional nodes in patients with Dukes B2 colorectal cancer could be used to stage their disease more accurately. METHODS: Using formalin-fixed, paraffin-embedded archival material, tumor samples were screened for K-ras mutations using a mutation-specific polymerase chain reaction method, followed by gel electrophoresis in a 96-well array. Patients with Dukes B2 tumors that have mutations in codon 12 or 13 of the K-ras gene were identified. RESULTS: Mutational analysis of the lymph nodes from these patients revealed an 80 percent (16/20) incidence of the same mutations in regional lymph nodes. None of the four patients with mutation-free nodes developed recurrence compared with 37.5 percent (6/16) with K-ras positive lymph nodes. CONCLUSIONS: The data suggest that patients with Dukes B2 colorectal cancers that have mutations in codon 12 or 13 of the K-ras gene are at high risk for the development of nodal metastases. Mutational analysis of the lymph nodes identifies high-risk patients who should be considered for adjuvant chemotherapy. Therefore, K-ras mutational analysis should be considered for molecular staging of colorectal cancer.

KW - AS-PCR

KW - Colorectal cancer

KW - K-ras

KW - Lymph nodes

KW - Micrometastasis

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=0034006937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034006937&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 155

EP - 162

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 2

ER -